点击 最 下方 关注《材料汇》 ， 点击"在看"和" "并分享 添加 小编微信 ，遇见 志同道合 的你 正文 未来产业由前沿技术驱动，当前处于孕育萌发阶段或产业化初期，是具有显著战略性、引领性、颠覆性和不确定 性的前瞻性新兴产业。大力发展未来产业，是引领科技进步、带动产业升级、培育新质生产力的战略选择。 | 地区 | 未来制造 | 未来信息 | 中国各地区的未来产业全景图 未来材料 | 未来能源 | 未来空间 | 未来健康 | | --- | --- | --- | --- | --- | --- | --- | | | 智能制造 激光制造 循环制造 共享制造 | 卫星互联网 量子信息; 大模型 | 先进基础材料升级 高性能碳纤维、先 | 核聚变 氢能 新型储能 | 载人航天 探月探火 ア星导航 深海作业装备 深海智能无人平台 | 细胞和基因技术 合成生物 脑 交互 | | | 生物制造 | | | | | | | | 纳米制造 | 下一代移动通信 | | 核能 | | | | | | | | | 临空无人系统 | | | | | | | | 先进高效航空器 | | | | | | | | 深海潜水器 | | ...

Group 1 - The core viewpoint of the news is that the Hong Kong IPO market is experiencing significant growth, with a notable increase in the number of new listings and total fundraising amounts in 2026 [1][2][4] - As of February 5, 2026, there have been 15 new IPOs in Hong Kong, representing a year-on-year increase of 87.50%, with total fundraising reaching 51.307 billion HKD, up 757.71% [1] - Eastroc Beverage has become the first IPO in Hong Kong for 2026 to raise over 10 billion HKD, totaling 10.1 billion HKD [1] Group 2 - The "2025 Hong Kong IPO Market and Secondary Market White Paper" indicates that there are over 270 companies planning to list, with 277 valid applications as of December 31, 2025 [2][3] - The majority of these applications are concentrated in the software services, healthcare, and industrial manufacturing sectors, accounting for over 60% of the total [3] - The average number of submissions per company is 1.4, indicating a strong influx of new companies into the Hong Kong market [3] Group 3 - Multiple institutions predict that the Hong Kong IPO market will remain robust in 2026, with estimates ranging from 150 to 200 new listings and total fundraising between 300 billion to 350 billion HKD [5] - Deloitte forecasts approximately 160 new IPOs with a minimum fundraising of 300 billion HKD, while PwC expects around 150 listings with total fundraising between 320 billion to 350 billion HKD [5] Group 4 - In 2025, A-share companies were a significant source for the Hong Kong IPO market, with 19 new A+H companies listed, raising a total of 126.946 billion HKD [6][7] - There are currently 93 A-share companies that have submitted applications to list in Hong Kong, including 10 with a market capitalization exceeding 100 billion RMB [7] Group 5 - The trend of leading mainland enterprises and A+H new stocks listing in Hong Kong is expected to continue in 2026, driven by the demand for international financing channels [8] - The influx of A-share companies is enhancing the quality and attractiveness of the Hong Kong capital market, providing stable cash flow and clear growth logic [8] Group 6 - Recent reforms by the Hong Kong Stock Exchange, including the introduction of the 18A and 18C rules, have significantly increased the market's appeal, particularly for biotech and technology companies [10][12] - The 18A rule has led to a rise in biotech listings, with 16 companies listed in 2025, and 27 companies currently applying under this rule [10][14] - The 18C rule has also attracted numerous unprofitable tech companies, with 5 companies listed in 2025 and a total fundraising of 59.15 billion HKD [13][14]

Financial Data and Key Metrics Changes - Adjusted EPS for Q2 was $0.46, up 10% year-over-year, while GAAP EPS increased to $0.24 from $0.22 in the prior year [19] - Total revenue for Q2 was $295.9 million, flat year-over-year on both an organic and reported basis, with foreign currency exchange contributing a 2% tailwind [19][20] - Adjusted gross margin was 68.5%, down from 70.5% last year, driven by unfavorable product and customer mix [21] - Adjusted operating margin reached 31.1%, up 100 basis points year-over-year, reflecting productivity gains and cost management [21][22] Business Line Data and Key Metrics Changes - Protein Sciences segment reported sales of $215.1 million, with organic revenue declining 1% but benefiting from foreign exchange [23] - Diagnostics and spatial biology segment sales were $81.2 million, down 4% year-over-year, with organic growth of 3% after accounting for divestitures [25] - Core reagents and assays delivered low double-digit growth, while proteomic analytical tools grew upper single digits [15][24] Market Data and Key Metrics Changes - Revenue from large pharma customers increased low double digits for the fourth consecutive quarter, while emerging biotech declined mid-single digits [9][20] - U.S. academic business saw a modest decline, partially offset by stable growth in Europe, resulting in a low single-digit decline overall for this end market [10] - China experienced mid-single-digit growth, marking its third consecutive quarter of growth, supported by R&D investments [10][20] Company Strategy and Development Direction - The company focuses on four strategic growth verticals: cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostic tools, which now represent 47% of total revenue [7] - The company is committed to maintaining a strong profitability profile while investing in strategic growth initiatives [6][18] - The upcoming fiscal year 2026 is significant as the company celebrates its 50th anniversary, with plans for various events [7] Management's Comments on Operating Environment and Future Outlook - Management noted that the operating environment is stabilizing but still challenging, with funding uncertainty affecting customer behavior in emerging biotech and U.S. academia [18] - There is optimism regarding the rebound in biotech funding and favorable U.S. appropriation bills, which are expected to support gradual improvement in end markets [18][19] - The company anticipates that headwinds from FDA Fast Track designations will moderate, allowing for improved growth in the future [26] Other Important Information - The company is actively pursuing M&A opportunities, with a focus on enhancing capabilities in cell therapy and proteomic analysis [81] - The acquisition of Wilson Wolf is on track, with expectations to complete it by the end of calendar year 2027 [13][81] Q&A Session Summary Question: Growth cadence and expectations for fiscal year 2026 - Management confirmed that underlying growth, excluding specific customer impacts, is expected to be mid-single digits for the year [30][32] Question: Drivers of gross margin trends - Management explained that gross margin pressures were due to unfavorable product mix and customer profiles, but improvements are expected in the latter half of the year [34][41] Question: Impact of AI on biotech demand - Management believes AI will enhance customer capabilities and drive demand for more complex materials, benefiting the company [42][45] Question: Biotech funding and timing of revenue impact - Management indicated that funding improvements typically show a six-month lag in revenue impact, with positive trends expected to continue [60][62] Question: Cell therapy customer impacts on GMP business - Management noted that the two large customers' Fast Track designations have created a temporary headwind, but underlying growth in the cell therapy business remains strong [64][66]

Core Insights - The event "Financial Vitality for Northern Xinjiang" was organized by the Wuhai Municipal Finance Bureau to promote financial policies benefiting enterprises and to facilitate government-financial-enterprise connections [1][6] - The event aimed to inject financial momentum into the high-quality economic development of Wuhai City, aligning with the "1571" work deployment and the spirit of the Wuhai Municipal Two Sessions [1][6] Group 1: Event Overview - The event included policy presentations by government departments, financial product introductions by financial institutions, and project promotion by enterprises, creating an efficient communication platform [1][6] - A total of 98 representatives from relevant government departments, financial institutions, and enterprises participated in the event [1][6] Group 2: Financial and Policy Insights - The Wuhai Development and Reform Commission and the Regional Economic Cooperation Bureau presented on the industrial development direction and planning during the 14th Five-Year Plan, outlining a clear industrial development blueprint [3][7] - The People's Bank of China Wuhai Branch and the National Financial Regulatory Administration Wuhai Regulatory Bureau provided interpretations of the latest financial credit policies to help enterprises grasp policy benefits [3][7] Group 3: Financial Products and Partnerships - Financial institutions such as Bank of China Wuhai Branch, Postal Savings Bank Wuhai Branch, Wuhai Bank, and Wuhai Shengda Financing Guarantee Co., Ltd. introduced their financial products, showcasing their service advantages tailored to enterprise needs [3][7] - Private enterprises like Inner Mongolia Derui Biotechnology Co., Ltd., Wuhai Xinqiao Logistics Co., Ltd., and Inner Mongolia Dongjing Zhongke New Materials Technology Co., Ltd. presented their development plans and financing needs, laying the groundwork for future cooperation [3][7] Group 4: Signing Ceremony and Future Plans - A signing ceremony was held where 32 cooperation agreements were reached, with a total signing amount of 9.8 billion yuan, and 12 agreements were signed on-site amounting to 4.5 billion yuan [3][7] - The Wuhai Municipal Finance Bureau plans to continuously improve the regular communication mechanism between government, finance, and enterprises, enhancing policy guidance and service support to facilitate enterprise financing [5][9]

Group 1 - The core viewpoint of the articles highlights the resilience of the US economy, with strong GDP growth and positive investor sentiment despite geopolitical tensions and the Federal Reserve's cautious stance on interest rates [1][2][4]. - In January, the S&P 500 index rose by 1.4%, with all eight sectors gaining, particularly the energy sector, which surged by 14.4% due to rising oil prices [1]. - The US GDP annualized growth rate for Q3 2025 was reported at 4.4%, slightly above market expectations, marking the highest growth rate in nearly eight quarters [1][2]. Group 2 - The Federal Reserve decided to pause interest rate changes during its first FOMC meeting of 2026, indicating a stable financial environment with ample liquidity, while inflation remains above the target [2]. - The earnings growth of the "Tech Seven" companies significantly outpaced the broader S&P 500, with projected earnings growth rates of 40.3% for 2025 compared to 15.4% for the S&P 500 excluding these companies [2]. - The S&P 500 index has shown a compound annual growth rate (CAGR) of approximately 6% over the last century and 12.8% over the past decade, indicating strong long-term performance [3]. Group 3 - The US technology stocks are leading in earnings growth compared to global markets, with the NASDAQ 100 expected to grow by 21.1% year-on-year [3]. - The necessity of investing in US equities is emphasized, as the US market accounts for 47.4% of global market capitalization, representing a significant opportunity for investors [3][6]. - The article suggests that a balanced investment strategy should include a mix of 60% stocks and 40% bonds, with potential diversification into gold, digital assets, and foreign stocks [6]. Group 4 - The outlook for the US economy remains positive, with expectations of a steady upward trend in the S&P 500, supported by the nomination of Kevin Walsh as the new Federal Reserve Chair [4]. - The article notes that the stock market's performance is crucial for political support, especially in an election year, suggesting that the government may take actions to bolster market confidence [4]. - Short-term market fluctuations may present buying opportunities for investors, as the overall sentiment remains optimistic despite potential volatility [4]. Group 5 - The article discusses the advantages of ETFs in the US market, highlighting their liquidity and diverse types, which cater to various investment strategies [5]. - It is noted that non-leveraged ETFs, particularly those tracking major indices, are less risky compared to individual stocks and are suitable for long-term holding [5]. - Investors are encouraged to consider sector-specific ETFs, such as those focused on semiconductors and biotechnology, to capitalize on industry trends [6].

2月4日（周三），恒生科技全天表现弱势，权重股腾讯控股受到"元宝风波"影响，盘中一度跌近4%。 截至16点港股收盘，恒生科技跌1.84%，日K"五连跌"。但资金面上看，南向资金下跌之际大幅加仓， 全天净流入约133亿港元，创近一周净流入新高。 ETF资金动向方面，恒生互联网ETF、港股通科技ETF、港股通互联网ETF2月4日均出现大额买单，连 续两日出现大额净流入，显示资金逆势布局，"越跌越买"。华夏基金分析称，资金之所以逆势加仓，或 基于三点： 1）港股科技相对A股、美股科技，估值处于近5年低位，恒生科技与创业板指收益差到历史高位，安全 边际高；2）港股科技板块占据AI应用端与商业化核心环节，增长确定性高；3）海外弱美元大趋势不 变，与南向资金共振，为港股后市流动性提供支撑。上述三大因素都将为港股科技未来价值回归创造条 件。 港股通科技ETF基金（159101.SZ）在深圳证券交易所上市，并支持T+0交易机制，为A股投资者提供低 门槛、免换汇的交易便利。场外投资者也可以逢低定投华夏港股通科技ETF联接C（025806.OF）。 逢低布局港股科技核心资产，可以关注港股通科技ETF基金（159101.SZ），被 ...

Group 1 - Hong Kong is actively supporting the national innovation and technology development strategy, leveraging financial resources to empower tech development and seize opportunities from the national "14th Five-Year Plan" [1] - In 2022, Hong Kong's stock market led globally with 119 companies listed, raising over HKD 280 billion, with approximately 70% of the funds coming from sectors like information technology, biotechnology, new energy, and advanced manufacturing [1] - The Hong Kong government has made significant investments in research and development, resulting in over 5,200 startups in the region, marking an 11% increase and a historical high [2] Group 2 - The government has implemented various support programs for different stages of tech development, including the "Industry-Academia-Research 1+ Plan" and the "New Industrial Acceleration Program" [2] - The Northern Metropolis is identified as a key area for tech development, facilitating collaboration with cities in the Guangdong-Hong Kong-Macao Greater Bay Area [2] - Hong Kong is focusing on talent cultivation through local universities and attracting global talent, with a HKD 3 billion "Frontier Technology Research Support Program" to draw top international researchers [3]

一低位：恒生科技指数最新估值为22倍，无论纵向看历史分位，还是横向相比纳斯达克（35倍）和A股 创业板指（43倍），都极具性价比； 一拐点：由于小作文引发情绪恐慌，恒生科技主要指数跌落年线（也称为"250日均线"）。该位置也是 本轮上行行情的支撑线，历次大行情（如2016~2017年、2020~2021年）均未显著跌破。近日破位下跌 之际，超20亿元资金涌入相关ETF，积极博弈修复反弹； 二催化：春节期间，DeepSeek大模型将更新升级；AI应用红包活动开启，两大催化有望加速AI国民化 和商业化进程，互联网平台广告、游戏、电商、传媒等传统业务也将迎来第二"增长极"。 截至2月4日，恒生科技指数自去年10月高点回撤超19%，触及历次回调极值。 华夏基金提示，港股短期回调为春季躁动提供配置机遇。 综合技术面、资金面动向，恒生科技、港股通科技等相关ETF或出现非理性下跌后的修复，即"一低位 一拐点二催化"底部布局机会。 如港股通科技ETF基金（159101.SZ）及其联接C（025806.OF），被动跟踪国证港股通科技指数，风格 不漂移、持仓透明，且接近满仓，布局效率高。从指数特征来看，其成分股精选港股通标的，流 ...

格隆汇2月3日丨特宝生物(688278.SH)公布，公司全资子公司厦门伯赛基因转录技术有限公司（以下简 称"伯赛基因"）于近日收到厦门市科学技术局、厦门市财政局、国家税务总局厦门市税务局联合颁发的 《高新技术企业证书》，证书编号为GR202535101170，发证时间为2025年12月25日，有效期三年。伯 赛基因本次通过高新技术企业认定系原证书有效期满后进行的重新认定。 ...

Group 1 - In January 2026, A-shares saw a significant increase in new accounts, totaling 4.9158 million, which is an 89% month-on-month increase from December 2025 and a 213% year-on-year increase from January 2025 [1][2] - The majority of new accounts were from individual investors, accounting for 4.9053 million, while institutional investors opened 10,554 accounts [2] - The new account figures for January 2026 surpassed all monthly totals from 2025, indicating a strong market sentiment and a rapid increase in market activity at the beginning of the year [2] Group 2 - Market analysts are generally optimistic about the future market trends, with many brokerage firms predicting that the market is in the second phase of a bull market driven by continuous inflow of new capital [3] - Key drivers for the A-share market include favorable domestic fundamentals, supportive policies, and ample liquidity, which are expected to sustain the spring market rally [3] - Analysts suggest focusing on sectors with limited downside and significant upside potential, particularly in brokerage stocks and banks that are performing well [4]